<DOC>
	<DOCNO>NCT02431481</DOCNO>
	<brief_summary>The purpose study characterize PK safety profile LEE011 follow single oral dose adult subject various degree renal impairment compare match group healthy subject normal renal function .</brief_summary>
	<brief_title>Evaluation Renal Function Impairment Pharmacokinetics LEE011</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Inclusion Criteria ( All Subjects ) : Male female ( sterile postmenopausal ) subject 1875 ( inclusive ) year age healthy determine absence clinically significant deviation normal medical history , physical examination , vital sign , electrocardiogram , clinical laboratory determination ( except renal impaired subject ) . Subjects must BMI 18 kg/m2 38 kg/m2 weight least 50 kg 120 kg . Additional inclusion criterion subject normal renal function : An absolute GFR determine MDRD equation conversion within normal range determine GFR &gt; 90 mL/min Inclusion Criteria ( subject impair renal function ) : Subjects must document stable renal disease without evidence renal progressive disease ( stable renal disease define significant change , stable absolute GFR , 4 week prior study entry . Exclusion Criteria ( All Subjects ) : Subject receive renal transplant time past immunosuppressant therapy History presence impair cardiac function Any surgical medical condition may significantly alter absorption , distribution , metabolism , excretion drug Administration CYP3A4/5 inhibitor inducer CYP3A4 substrates narrow therapeutic window Administration medication prolong QT interval Subject history immunodeficiency disease , include HIV , confirm ( HIV1 , HIV2 ) test Receipt investigational product another clinical trial within 4 week dose Exclusion Criteria ( subject impair renal function ) : Severe albuminuria &gt; 300 mg/day Subjects undergoing method dialysis Subjects renal impairment due hepatic disease ( hepatorenal syndrome ) Other protocoldefined Inclusion/Exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>